The elderly patients belong to special drug users, and are more likely to have adverse reactions due to the influence of basic diseases, liver and kidney functions, combined drugs, etc. The reporter learned from the official website of the State Food and Drug Administration that recently, the State Food and Drug Administration mentioned in its reply to the Proposal on Attaching Importance to the Safety of Medication for the Elderly and Improving the Level of Pharmaceutical Service (No. 00079) of the Fifth Session of the 13th National Committee of the CPPCC that with the aging of the population and the improvement of the medical and health care system, the amount of drugs used by the elderly is increasing, and the proportion of adverse reactions continues to rise, It is necessary to strengthen the monitoring, evaluation, analysis and application of adverse drug reactions in the elderly. In recent years, the State Food and Drug Administration has continued to strengthen the monitoring of adverse drug reactions in elderly people. According to the monitoring data of adverse drug reactions in 2021, the reports of adverse drug reactions of elderly patients over 65 years old accounted for 31.2% of the total population reports. In its reply, the State Food and Drug Administration said that the State Food and Drug Administration had timely organized technical forces to assess the increased risk of drug use involving the elderly found in the monitoring, and took measures according to law to ensure the safety of drug use for the elderly. For example, in 2015, the Adverse Drug Reaction Information Bulletin was issued, suggesting that the elderly should be cautious in using metoclopramide; In 2019, the instructions were uniformly revised for the risks caused by intravenous injection of human immunoglobulin, requiring that patients over 65 years old should not use drugs beyond the recommended dose; In 2021, the instructions of Xiaochaihu preparation, Anshen Bunao preparation, Ganmao Qingre preparation and Wudi ointment for external use will be revised uniformly, indicating that "the elderly and the infirm should take it under the guidance of doctors", and the instructions of Shiduqing preparation and Joint Pain killing ointment (OTC drug) will be revised uniformly, indicating that "the elderly patients should take it under the guidance of doctors"; In 2022, the instructions for proton pump inhibitors will be revised to warn elderly patients that their use may increase the risk of fracture. In the next step, the State Food and Drug Administration will continue to monitor and evaluate the adverse drug reactions of the elderly, pay close attention to the public's demand for drug safety of the elderly, and protect the life safety and health of the elderly. (Outlook New Times)